Penn Capital Management’s Travere Therapeutics TVTX Stock Holding History

Penn Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$850K	Buy	14,968 +2,292	+18%	+$102K	0.05%	127
2026 Q1	$377K	Buy	12,676 +809	+7%	+$24.2K	0.03%	165
2025 Q4	$453K	Sell	11,867 -15,137	-56%	-$492K	0.04%	152
2025 Q3	$645K	Buy	27,004 +7,680	+40%	+$144K	0.05%	132
2025 Q2	$286K	Sell	19,324 -1,770	-8%	-$29.3K	0.02%	147
2025 Q1	$378K	Buy	+21,094	New	+$428K	0.04%	137

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Penn Capital Management's TVTX Position: Q2 2026 in Review

Penn Capital Management increased its Travere Therapeutics (TVTX) stake by 18% in Q2 2026, buying an estimated $102K and bringing the position to 14,968 shares worth $850K. The position accounts for 0.05% of the portfolio, ranked #127.

Penn Capital Management first reported a position in TVTX in Q1 2025 and has held it in 6 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Penn Capital Management held 14,968 shares of Travere Therapeutics worth $850K as of Q2 2026.
Penn Capital Management bought 2,292 Travere Therapeutics shares in Q2 2026, an estimated $102K.
Travere Therapeutics made up 0.05% of Penn Capital Management's portfolio in Q2 2026, its #127 holding.
Penn Capital Management first reported a position in Travere Therapeutics in Q1 2025 and has held it in 6 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.